Sang-Woo Park
Directeur Général chez NKMAX CO., LTD.
Fortune : 794 962 $ au 30/04/2024
Profil
Mr. Sang-Woo Park is a Chief Executive Officer at Nkmax Japan, Inc., a Chief Executive Officer at Atgen Japan, a Chief Executive Officer at Nkmax H&D Co. Ltd., a Chief Executive Officer at coAsia Biotech Corp., a Chief Executive Officer at Atgen H&D, a Chief Executive Officer at ATGen America, Inc., a Chief Executive Officer at ATGen Canada, Inc., a Chief Executive Officer & Director at NKMAX Co., Ltd.
(South korea) and a Chairman & Chief Executive Officer at NKMAX Co., Ltd.
He is on the Board of Directors at NKGen Biotech, Inc., NKMAX Co., Ltd.
(South korea) and NKGen Operating Biotech, Inc. Mr. Park was previously employed as a Chief Executive Officer & Director by J way Co., Ltd.
He received his undergraduate degree from Korea University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
1,74% | 13/12/2023 | 397 378 ( 1,74% ) | 786 808 $ | 30/04/2024 |
NKMAX CO., LTD.
0,01% | 26/01/2024 | 5 418 ( 0,01% ) | 8 154 $ | 31/03/2024 |
Postes actifs de Sang-Woo Park
| Sociétés | Poste | Début |
|---|---|---|
| NKMAX CO., LTD. | Directeur Général | 14/01/2002 |
| ATGen America, Inc. | Directeur Général | 01/02/2014 |
| ATGen Canada, Inc. | Directeur Général | 01/09/2013 |
Atgen H&D
 Atgen H&D Pharmaceuticals: OtherHealth Technology Atgen H&D develops protein products. Sang-Woo Park has been the CEO of the South Korean company since 2016. | Directeur Général | 01/01/2016 |
NKMAX Co., Ltd.
 NKMAX Co., Ltd. Pharmaceuticals: MajorHealth Technology NKMAX Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following business divisions: Immunity Cell Cure, Immunodiagnosis Kit, Health Functional Foods, and Bio Research. The company was founded on January 14, 2002 and is headquartered in Seongnam-si, South Korea. | Directeur Général | 01/01/2002 |
| Nkmax H&D Co. Ltd. | Directeur Général | 01/06/2016 |
coAsia Biotech Corp.
 coAsia Biotech Corp. BiotechnologyHealth Technology Part of NKMAX Co., Ltd. (South Korea), coAsia Biotech Corp. manufactures biological products. Sang-Woo Park has been the CEO of the Thai company since 2016. coAsia Biotech was acquired by NKMAX Co., Ltd. (South Korea) on February 28, 2018 for $0.10 million. | Directeur Général | 01/04/2016 |
| Atgen Japan | Directeur Général | 01/09/2017 |
NKGen Biotech, Inc.
 NKGen Biotech, Inc. BiotechnologyHealth Technology NKGen Biotech, Inc. is a biotechnology company which engages in harnessing the immune system through natural killer cell therapies. It develops a proprietary stabilizing peptide, monoclonal antibodies, and recombinant proteins for research use. The company was founded in 2002 and is headquartered in Santa Ana, CA. | Fondateur | 01/01/2002 |
| ░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Anciens postes connus de Sang-Woo Park
| Sociétés | Poste | Fin |
|---|---|---|
| ░ ░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░ | - |
Formation de Sang-Woo Park
| Korea University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| J WAY CO., LTD. | Consumer Services |
| NKMAX CO., LTD. | Health Technology |
| Entreprise privées | 9 |
|---|---|
| ATGen Canada, Inc. | |
| ATGen America, Inc. | |
Atgen H&D
Atgen H&D Pharmaceuticals: OtherHealth Technology Atgen H&D develops protein products. Sang-Woo Park has been the CEO of the South Korean company since 2016. | Health Technology |
NKMAX Co., Ltd.
NKMAX Co., Ltd. Pharmaceuticals: MajorHealth Technology NKMAX Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following business divisions: Immunity Cell Cure, Immunodiagnosis Kit, Health Functional Foods, and Bio Research. The company was founded on January 14, 2002 and is headquartered in Seongnam-si, South Korea. | Health Technology |
coAsia Biotech Corp.
coAsia Biotech Corp. BiotechnologyHealth Technology Part of NKMAX Co., Ltd. (South Korea), coAsia Biotech Corp. manufactures biological products. Sang-Woo Park has been the CEO of the Thai company since 2016. coAsia Biotech was acquired by NKMAX Co., Ltd. (South Korea) on February 28, 2018 for $0.10 million. | Health Technology |
| Nkmax H&D Co. Ltd. | |
| Atgen Japan | |
NKGen Biotech, Inc.
NKGen Biotech, Inc. BiotechnologyHealth Technology NKGen Biotech, Inc. is a biotechnology company which engages in harnessing the immune system through natural killer cell therapies. It develops a proprietary stabilizing peptide, monoclonal antibodies, and recombinant proteins for research use. The company was founded in 2002 and is headquartered in Santa Ana, CA. | Health Technology |
| Nkmax Japan, Inc. |
